Highmark adopts Xdx gene expression blood test

Highmark, an independent licensee of the Blue Cross Blue Shield Association, is using XDx's AlloMap Molecular Expression test.

AlloMap is a non-invasive gene expression blood test used to manage rejection in stable heart transplant recipients and may aslo reduce the need for biopsies for stable patients.

AlloMap measures the expression levels of 20 genes and the combined expression of these genes is represented as an AlloMap test score.

West Penn Allegheny Health System Cardiovascular Institute Medical Director Srinivas Murali said the addition of AlloMap testing has improved their ability to provide quality care to heart transplant patients.